NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
1.84
Dollar change
+0.03
Percentage change
1.66
%
Index- P/E- EPS (ttm)-6.99 Insider Own2.90% Shs Outstand2.26M Perf Week5.14%
Market Cap4.16M Forward P/E- EPS next Y-0.85 Insider Trans0.00% Shs Float2.19M Perf Month28.67%
Enterprise Value-11.69M PEG- EPS next Q-0.83 Inst Own9.88% Short Float3.06% Perf Quarter15.72%
Income-7.35M P/S- EPS this Y64.49% Inst Trans23.31% Short Ratio0.04 Perf Half Y-39.47%
Sales0.00M P/B0.25 EPS next Y73.93% ROA-44.25% Short Interest0.07M Perf YTD-42.32%
Book/sh7.47 P/C0.26 EPS next 5Y62.35% ROE-49.58% 52W High23.80 -92.27% Perf Year-50.55%
Cash/sh7.01 P/FCF- EPS past 3/5Y67.61% 45.91% ROIC-43.53% 52W Low1.15 60.00% Perf 3Y-97.93%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility6.26% 6.78% Perf 5Y-99.80%
Dividend TTM- EV/Sales- EPS Y/Y TTM67.95% Oper. Margin- ATR (14)0.12 Perf 10Y-99.91%
Dividend Ex-Date- Quick Ratio9.02 Sales Y/Y TTM- Profit Margin- RSI (14)62.55 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio9.02 EPS Q/Q77.86% SMA2010.01% Beta0.58 Target Price12.00
Payout- Debt/Eq0.00 Sales Q/Q- SMA5023.01% Rel Volume0.14 Prev Close1.81
Employees6 LT Debt/Eq0.00 EarningsMay 22 BMO SMA200-33.86% Avg Volume1.70M Price1.84
IPOMar 13, 2014 Option/ShortNo / Yes EPS/Sales Surpr.30.34% 0.00% Trades Volume237,870 Change1.66%
Date Action Analyst Rating Change Price Target Change
May-22-20Downgrade B. Riley FBR Buy → Neutral $11 → $8
Feb-04-20Initiated Craig Hallum Buy $18
Jan-30-20Resumed Cantor Fitzgerald Overweight $9 → $14
Dec-02-19Initiated Canaccord Genuity Buy
Dec-12-18Initiated B. Riley FBR Buy $28
Aug-02-18Reiterated Maxim Group Buy $30 → $27
Jul-13-18Initiated Stifel Buy $35
Jul-12-18Initiated Cantor Fitzgerald Overweight $59
Jun-12-18Reiterated H.C. Wainwright Buy $24 → $43
Mar-15-18Upgrade Maxim Group Hold → Buy $14
May-27-25 08:00AM
May-22-25 08:04AM
08:00AM
May-13-25 08:00AM
May-10-25 11:55AM
07:30AM Loading…
May-06-25 07:30AM
May-01-25 12:15PM
Apr-28-25 08:00AM
Apr-17-25 08:30AM
Apr-15-25 08:30AM
Apr-10-25 08:00AM
Apr-02-25 04:10PM
Mar-20-25 08:55AM
Nov-15-24 08:29AM
Sep-25-24 08:00AM
09:00AM Loading…
Sep-20-24 09:00AM
Sep-19-24 07:00AM
Jun-22-24 09:52AM
Apr-10-24 06:30AM
Apr-05-24 09:53AM
Apr-04-24 05:06PM
Mar-15-24 09:00AM
Nov-21-23 07:32AM
Nov-20-23 04:32PM
Sep-26-23 08:30AM
Sep-22-23 04:05PM
Aug-10-23 11:08AM
Jul-14-23 09:20AM
Jul-10-23 08:00AM
Jun-01-23 08:05AM
08:00AM Loading…
08:00AM
May-09-23 07:00AM
May-04-23 04:00PM
Mar-29-23 05:00PM
Feb-08-23 08:00AM
Jan-06-23 06:34AM
Jan-04-23 08:00AM
Dec-14-22 05:00PM
Sep-14-22 12:00PM
Aug-04-22 08:00AM
Jul-18-22 11:43AM
Jul-13-22 10:53AM
Jul-07-22 10:18AM
07:30AM
Jun-17-22 04:15PM
Jun-15-22 10:47AM
May-17-22 08:00AM
07:30AM
May-02-22 07:00AM
Apr-28-22 07:00AM
Apr-26-22 08:30AM
Mar-29-22 10:18AM
Jan-11-22 07:30AM
Jan-10-22 07:30AM
Nov-08-21 07:30AM
07:00AM
Nov-01-21 12:38PM
10:10AM
Oct-11-21 08:00AM
Aug-24-21 12:03PM
Aug-19-21 11:49AM
08:00AM
Aug-16-21 08:00AM
Aug-11-21 12:48PM
Aug-10-21 03:41PM
Aug-05-21 07:00AM
Aug-03-21 04:49AM
Aug-02-21 09:26AM
07:30AM
Jul-29-21 08:30AM
Jun-04-21 06:57AM
May-13-21 07:50AM
06:30AM
May-06-21 08:30AM
May-03-21 08:30AM
Mar-19-21 07:23AM
Mar-18-21 07:00AM
06:30AM
Mar-16-21 08:00AM
Mar-11-21 08:30AM
Feb-16-21 09:29AM
06:48AM
Feb-11-21 11:16AM
Feb-04-21 01:30AM
Jan-26-21 08:00AM
Jan-19-21 08:00AM
Dec-17-20 07:00AM
Dec-04-20 09:08AM
Nov-12-20 07:00AM
06:45AM
Nov-10-20 08:40AM
Nov-09-20 08:00AM
Nov-05-20 08:30AM
Oct-20-20 08:31AM
Sep-10-20 08:49AM
Aug-06-20 07:00AM
06:50AM
Jul-30-20 08:30AM
Jul-22-20 10:34AM
Jul-14-20 05:31PM
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.